1. How many of the following patients (excluding clinical trial patients) are currently being managed by your Health Trust:
All Urothelial cancer (UCC, transitional carcinoma, TCC) patients
Metastatic* or locally advanced* Urothelial cancer (UCC, transitional carcinoma, TCC) patients
2. Of the metastatic* or locally advanced* Urothelial cancer (UCC, transitional carcinoma, TCC) patients, please state the number of patients currently being treated with the following therapies:
Cisplatinum single agent
Cisplatinum in combination with another agent
Carboplatinum single agent
Carboplatinum in combination with another agent
Any other chemo regimen without cisplatinum or carboplatinum
Pembrolizumab (Keytruda)
Atezolizumab (Tecentriq)
3. If your trust does not treat these cancers and you refer your patients to another trust, please state to which trust patients are referred:
